middle.news
Immutep’s Efti Combo Sparks Immune Surge in Hard-to-Treat Sarcomas
8:27am on Thursday 13th of November, 2025 AEDT
•
Healthcare
Read Story
Immutep’s Efti Combo Sparks Immune Surge in Hard-to-Treat Sarcomas
8:27am on Thursday 13th of November, 2025 AEDT
Key Points
51.5% median tumour hyalinization/fibrosis achieved with efti, radiotherapy, and KEYTRUDA
Strong immune activation evidenced by significant rises in cytokines and chemokines
Efficacy observed across 10 soft tissue sarcoma subtypes, including rare aggressive forms
Early biomarker increases correlate with improved pathological responses
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE